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We have identified in Caenorhabditis elegans a homologue of the vertebrate Crim1, crm-1, which encodes a putative transmembrane protein
with multiple cysteine-rich (CR) domains known to have bone morphogenetic proteins (BMPs) binding activity. Using the body morphology of C.
elegans as an indicator, we showed that attenuation of crm-1 activity leads to a small body phenotype reminiscent of that of BMP pathway
mutants. We showed that the crm-1 loss-of-function phenotype can be rescued by constitutive supply of sma-4 activity. crm-1 can enhance BMP
signaling and this activity is dependent on the presence of the DBL-1 ligand and its receptors. crm-1 is expressed in neurons at the ventral nerve
cord, where the DBL-1 ligand is produced. However, ectopic expression experiments reveal that crm-1 gene products act outside the DBL-1
producing cells and function non-autonomously to facilitate dbl/sma pathway signaling to control body size.
© 2007 Elsevier Inc. All rights reserved.Keywords: C. elegans; crm-1; Body size; BMP pathwayIntroduction
Bone Morphogenetic Proteins (BMPs) control a variety of
cellular processes required for proper differentiation of many
organs in vertebrates (Yamamoto and Oelgeschlager, 2004). In
Caenorhabditis elegans, the BMP-like ligand, DBL-1, is
required for determining body size and male sensory organ
patterning (Morita et al., 1999; Suzuki et al., 1999). In addition,
conserved signaling molecules acting in the BMP pathway have
been identified. They include the receptors, DAF-4 and SMA-6
(Estevez et al., 1993; Krishna et al., 1999), and the Smad
proteins, SMA-2, SMA-3, and SMA-4 (Savage et al., 1996).
Mutations in their encoding genes generate small body
morphology and sensory organ patterning defects.
A number of previous studies have reported that BMP
signaling is modulated by secreted proteins that bind BMPs in
the extracellular space (Fig. 1A). For examples, Chordin,
Noggin, Follistatin and Cerberus antagonize BMP signalling by
directly association with BMP ligands (Smith and Harland,⁎ Corresponding author. Fax: +852 2358 1559.
E-mail address: bokchow@ust.hk (C. King Lau).
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of these extracellular factors can also positively regulate BMP
signalling. In Drosophila, short gastrulation (sog) mutant
displays a dorsalization phenotype and sog acts against deca-
pentaplegic (dpp) in the embryonic development (Ferguson and
Anderson, 1992). On the other hand, sog is required for
maximal dpp activity for the formation of dorsal most tissues
(Decotto and Ferguson, 2001). Thus, sog functions both as an
antagonist and an agonist of dpp in a context-dependent
manner. However, no such positive nor negative regulator of the
Bmp signalling pathway has been identified in C. elegans. It is
tempting to find out if such a regulator exists and whether it
shares common property as its counterparts in other animal
models.
CHORDIN and SOG proteins are characterized by their
multiple cysteine-rich repeats (CR) (Sasai et al., 1994). The
only CR domain-containing protein in C. elegans was first
noted as a putative protein with similarity to the vertebrate
CRIM1 (Cysteine-rich Motor Neuron 1) protein (Kolle et al.,
2000). Overexpression of a truncated product of this C. elegans
ortholog in Xenopus embryos can induce a secondary axis
similar to that induced by chordin or procollagen IIA mRNA
Fig. 1. Vertebrate Bmp4 can functionally substitute dbl-1. (A) A model of the BMP signaling pathway where cysteine-rich (CR) domain-containing proteins function
as both positive or negative regulator. (B–D) dbl/sma pathway controls worm body length. (C) A dbl-1mutant have shorter body as compared with a wild-type animal
(B). (D) A dbl-1 mutant expressing Xenopus Bmp4 has its body length restored (D). Scale bar=100 μm.
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is implicated in negative regulation of BMP signaling event.
Consistent with this notion, overexpression of CRIM1 in human
cells effectively reduces the secretion of BMP4 (Wilkinson et
al., 2003). On the other hand, loss-of-function studies on Crim1
in zebrafish and mice are less conclusive. The elimination of the
zebrafish Crim-1 activity shows defect in somite and vascular
developments, but the phenotypes do not appear to be
associated with an altered BMP level (Kinna et al., 2006).
The disruption of Crim1 gene in mice results in a severe and
complex phenotype affecting numerous organogenesis events,
and there is no evidence of its role in early embryonic patterning
(Pennisi et al., 2007). Although C. elegans crm-1 (CRIM-1
homolog) has been identified, its expression and regulatory
function in C. elegans development remains undefined.
In this paper, the phenotype of C. elegans crm-1 mutant in
different genetic backgrounds is examined to evaluate its
regulatory relationship with the BMP pathway. We provide
genetic evidence that crm-1 facilitates BMP signaling in
controlling body size. We showed that crm-1 acts along the
BMP pathway and its activity is dependent on the presence of the
DBL-1 ligand. crm-1 expression profile and the effect of ectopic
crm-1 expression were also evaluated to establish a working
model of CRM-1 function. We unambiguously demonstrate that
CRM-1 functions non-autonomously to promote dbl-1 activity.
Materials and methods
C. elegans strains
Nematode strains were cultured and maintained according to the standard
procedures described by Brenner (1974) or otherwise indicated. The following
mutations were used: sma-4(e729), sma-6(e1482), sma-6(wk7), lon-1(e185),
sma-2(e502), dpy-2 (e8), dbl-1(nk3), him-5(e1490) and crm-1(tm2218).
RNA interference of the crm-1 gene
Double-stranded RNA interference (RNAi) was performed by both dsRNA
microinjection and bacterial feeding methods. For injection purpose, linearizedplasmid of full-length EST (yk240a9) in pBluescript SK(−) was used for in vitro
RNA synthesis. The complementary strands were annealed to generate dsRNA
for microinjection (Fire et al., 1998). The dsRNAs were introduced into the
gonad of young adult hermaphrodites at a concentration of 1–3 μg/μl with TE
buffer as control. To generate a large number of animals for quantitative
analysis, we adopted the bacterial feeding method. A SpeI to AgeI fragment of
the crm-1 gene was released from the cDNA clone yk240a9 and subcloned into
the L4440 vector. The plasmid was transformed into an RNAseIII-deficient E.
coli strain HT115(DE3) (Timmons et al., 2001). The optimized bacterial feeding
protocol for young adult hermaphrodites was described by Kamath et al. (2001)
where empty vector harboring HT115(DE3) was used as control.
Body-length measurement and male tail phenotype characterization
L4 hermaphrodites grown at 20 °C were transferred to fresh NGM plates or
RNAi-feeding bacteria plates. Five days later, 100 F1 adult hermaphrodites were
randomly photographed under the 5× or 10× objectives with SPOT RT camera
(Diagnostic Instruments). Their body length was measured through a scale
adjustment with SPOT RT v3.4.5 software and was presented as mean length
with standard error. The male tails were examined by Nomarski microscopy
(NN50). Of the transgenic strains, only transformed worms carrying the markers
were imaged and scored.
Hypodermal ploidy measurements
The intensity of DAPI staining of the hypodermal nuclei in the
hermaphrodite was determined from video-microdensitometry as described by
Lozano et al. (2006). Nuclear images were captured as described above. The
images were analyzed in Adobe Photoshop 7.0. The C values of hypodermal
nuclei were calculated by dividing their DAPI-based densitometric value by an
average of the values from 10 ventral cord nuclei in the same animal. Twenty
hypodermal nuclei were scored for each young adult worm, and 15–20 worms
were scored to obtain the average ploidy of the hypodermis.
Gene reporter constructs
Two kilobases of the genomic sequence upstream of the putative start
codons of crm-1a and crm-1b were cloned into pPD95.75 green fluorescence
protein (gfp) reporter vector, respectively. crm-1a genomic fragment spanning
from putative exon 1 to 3′UTR (from +5 bp to +7105 bp) was subsequently
inserted after unc-54 3′UTR to generate pcrm-1a∷gfp reporter. Genomic
fragment from putative exon 1 of crm-1b to its 3′UTR (from +1 bp to +9605 bp)
was cloned after unc-54 3′UTR to generate pcrm-1b∷gfp. The promoter region
Table 1
Effect of crm-1 RNAi treatment on body length
* Significant difference pb0.001.
97W.Y. Fung et al. / Developmental Biology 311 (2007) 95–105(∼1500 bp) of dbl-1 (T25F10.2) was amplified by PCR and inserted into a red
fluorescence protein (RFP) vector (from pDsRed2-N1). This dbl-1 promoter
fragment was sufficient to transcribe authentic dbl-1 cDNA in the ventral nerve
cord for dbl-1 mutant rescue. The promoter region (∼1200 bp) of unc-47 was
also amplified by PCR and then cloned into pPD95.75 GFP reporter plasmid and
the RFP vector to generate punc-47∷gfp and punc-47∷rfp, respectively. Germ
line transformation with different reporter genes was carried out as described
(Mello et al., 1991). All transgene plasmids were co-transformed with either the
dominant rol-6 gene or crm-1b∷gfp as the selection marker.
Ectopic expression constructs
Ectopic expression of vertebrate gene products in worm was carried out as
follows: either the Xenopus Bmp4 cDNA (a gift from H.F. Kung) or mouse
Nodal cDNA (a gift from E.J. Robertson) was inserted between the 1.5 kb of
the dbl-1 promoter and unc-54 3′UTR in the pPD95.75 vector. dbl-1(nk3)
mutant animals were used as recipients in these rescue experiments. The dbl-1
(nk3)mutant animals carrying these XBmp4 and mouse Nodal cDNA transgenes
were examined for transgene expression by RT-PCR and were monitored for
their respective body lengths and male tail phenotypes.
To express the sma-4 cDNA specifically at the hypodermal layer, wild type
and mutant animals were transformed with plasmid with a sma-4 cDNA
(yk1195d06) driven by a one-kilobase dpy-13 promoter (Ko and Chow, 2002).
To express crm-1 ectopically in GABAnergic neurons, crm-1(tm2218) mutant
animals were transformed with a plasmid containing crm-1a cDNA (yk240a9)
driven by the 1.3 kb unc-47 promoter (Eastman et al., 1999) to generate
transgenic line wxEx65. The same unc-47 promoter was used to express dbl-1
cDNA (yk1350b03) ectopically in the dbl-1 (nk3) mutant to generate transgenic
line wxEx67. The rescued crm-1 mutant by a 9.1 kb crm-1 genomic fragment
carrying the entire crm-1 locus (wxEx66) and the rescued dbl-1 mutant by
expressing the dbl-1 cDNA using the 1.5 kb dbl-1 promoter (wxEx68) were
treated as the positive control. These same constructs were also employed
(injected at 200 ng/μl) to overexpress crm-1 or dbl-1 in the wild type animal. At
least three independent lines each with transmission efficiency above 60% were
scored for each specific transgene activity and were subjected to crm-1 RNAi
feeding.Results
dbl-1 is the functional homologue of vertebrate BMP4
Genetic screening in C. elegans for small body size mutants
uncovered many sma alleles, which correspond to mutations in
genes encoding components in the dbl/sma signaling pathway
(Savage-Dunn et al., 2003). The secreted ligand encoded by
dbl-1 is expressed in the neurons along the ventral nerve cord
and can trigger signaling events via the SMA-6/DAF-4
receptors and the Smad transducer molecules in the hypodermis
(Morita et al., 1999; Savage et al., 1996; Yoshida et al., 2001;
Wang et al., 2002). DBL-1 ligand was predicted to be a member
of the gene family consisting of Vg1, DPP and BMP with its C-
terminus most closely related to NODAL (Morita et al., 1999).
The Fitch–Margoliash algorithm, however, suggests DBL-1 to
have a closer resemblance to BMP4/2 (Suzuki et al., 1999). To
resolve the functional equivalence of DBL-1 in vertebrates, we
tested the ability of BMP4 and NODAL to rescue the dbl-1
mutant phenotype (Fig. 1C). Expressing a full-length Xenopus
Bmp4 cDNA with dbl-1 promoter reverted the small body
mutant phenotype to wild-type (Fig. 1D). Healthy adult
hermaphrodites have a body length ranging from 1.10 mm to
1.40 mm with a mean of 1.23±0.06 mm (Fig. 1B and Table 1).
These Xenopus Bmp4-rescued dbl-1 animals, however, dis-played a Lon phenotype (1.39±0.05 mm), a feature resembling
animals over-expressing nematode dbl-1 (1.40±0.07 mm)
(Table 1). Expression of the full-length mouse Nodal cDNA
by the same promoter could not restore the body size of dbl-1
mutants (0.83±0.04 mm). Therefore, the Bmp4 gene, like dbl-
1, acts in a dose-dependent manner to control the body size.
When this Bmp4 transgene was introduced into sma-6(wk7)
mutants, the mean body length remained at 0.81±0.03 mm. As
the ligand encoding transgene was actively transcribed as
monitored by RT-PCR (data not shown), the differential effects
in these two genetic backgrounds suggest that the vertebrate
BMP4 also acts through the SMA-6 receptor, and DBL-1 is a
functional equivalent of vertebrate BMP4 but not NODAL.
crm-1 mutant animals display the small phenotype
With the nematode DBL-1 functioning as a BMP4
equivalent, is it regulated by extracellular protein molecules
carrying CR domains? A Crim1-like-gene has been identified
as the only annotated worm protein with CR domains. It was
named crm-1. C. elegans crm-1 has five transcripts, namely
crm-1a, crm-1b, crm-1c, crm-1d, crm-1e, represented by full
length expressed sequence tags (Fig. 2A). These alternatively
spliced isoforms have the longest one, crm-1b, encoding a
membrane bound product with an N-terminal signal peptide, an
insulin-like growth factor-binding protein (IGFBP) domain, and
six CR domains juxtaposed to a putative transmembrane
domain near the C-terminus (Fig. 2B).
To investigate the relevance of this gene in BMP signaling
events, we obtained a deletion allele from the National
Table 2
Hypodermal ploidy measurement of mutants
Genotype Hypodermal ploidy (C) a n b
Wild type (N2) 8.8 (±0.6) 18
crm-1 (tm2218) 7.0 (±0.7) c 19
crm-1 (RNAi) 6.3 (±0.9)c 20
sma-2 (e502) 5.7 (±0.6)c 16
dpy-2 (e8) 8.1 (±0.8) 15
a Mean (±95% confidence interval).
b n=sample size.
c Significant difference. p values were calculated by unpaired t-test; a
p-valueb0.005 is considered statistically significant.
Fig. 2. CRM-1 is a conserved molecule with multiple CR domains. (A) Genomic
organization of crm-1 locus with the five transcripts: crm-1a, crm-1b, crm-1c,
crm-1d, crm-1e depicted. (B) All CRM-1 isoforms contain N-terminal signaling
peptide (SP) sequences, but different numbers of CR domains. crm-1b transcript
encodes a product with an additional insulin-like growth factor-binding protein
domain (IGFBP) where predicted products derived from crm-1c and crm-1e
transcripts lack transmembrane domain.
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carries a 192 bp deletion and a single nucleotide insertion.
Most of the fourth intron and approximately half of the fifth
exon of crm-1a gene have been removed (Fig. 2A). Transcript
analyses established that two truncated mRNA species from
crm-1 locus were made (data not shown). Reference to the
wild-type crm-1a transcript, one truncated species has no
splicing of intron 4 and encodes a partial protein with only
one authentic CR domain on the N-terminus. The other
transcript adopts a cryptic splice site to regenerate an ORF
containing only five out of the seven authentic CR domains.
Thus, this allele is predicted to represent a loss-of-function of
crm-1, if it is not a null. Consistent with this notion,
homozygous crm-1(tm2218) animals showed a 10% reduction
in body length (1.11±0.03 mm, pb0.001) (Table 1). This
phenotype could be rescued by introducing a 9.1 Kb genomic
fragment encompassing the entire crm-1a transcription unit.
On the other hand, when the crm-1 gene activity was reduced
in wild-type animals by dsRNA injection or bacteria-mediated
dsRNA interference using a two-kilobases fragment spanning
most of the CR-domains-coding region, a more severe small
body phenotype with a mean body length of 1.03±0.08 mm
was observed. This Sma phenotype is similar to that of dbl-1
and a number of sma mutants, all of which display a range of
body lengths from 0.60–1.00 mm (mean=0.82±0.03 mm)
(Table 1).
When we performed crm-1 RNAi knock-down on the crm-1
(tm2218) mutant, a further reduction in body length was noted.
A mean body length similar to RNAi-treated wild-type animals
was observed (1.04±0.09 mm, pb0.001). Collectively, the
results imply that crm-1(tm2218) is a loss-of-function allele
with residual activity, and crm-1(RNAi) mutant with stronger
phenotype was used in most of the subsequent loss-of-functionanalyses. When crm-1 activity was increased by introducing
more copies of 9.1 kb crm-1 wild-type genomic fragment with
full activity, no increase of body length was observed (1.23±
0.08 mm). That means whereas the availability of other
regulatory components is limiting in wild-type animals, an
increase of the crm-1 activity alone was not sufficient to extend
the body length.
Since mutations in the C. elegans dbl/sma pathway also
affects patterning of male-specific sensory rays and spicule
formation in the male tail (Savage et al., 1996; Baird and
Ellazar, 1999, Morita et al., 1999), we scored the crm-1(RNAi)
and the crm-1(tm2218) population for male tail abnormality.
None of these animals exhibited any defect in their male sex
organs, indicating that crm-1 may not be required in the dbl-1/
sma signaling events in the male tail (data not shown).
crm-1 controls body size via endoreplication
dbl-1 and other components in BMP pathway have been
reported to control endoreplication in the hypodermis after the
L4/adult moulting process (Flemming et al., 2000, Morita et al.,
2002, Lozano et al., 2006). We sought to determine if the crm-1
mutant exhibits a similar cellular defect, and similarities
between crm-1 and the dbl/sma mutants were found. Wild-
type animals had a mean ploidy of 8.8±0.6C (Table 2). sma
mutants, e.g., sma-2, had a mean ploidy of 5.7±0.6C (n=16,
pb0.0005) while dpy-2 acting independent of the dbl pathway
had a normal hypodermal ploidy. Endoreplication of hypoder-
mal nuclei was reduced in both crm-1(tm2218) animals (7.0±
0.7C, n=19, pb0.0005) and crm-1(RNAi) animals (6.3±0.9C,
n=20, pb0.0005). The respective reduction in ploidy suggests
that crm-1, like the other components in the BMP pathway,
controls body size via regulation of endoreplication in the
hypodermis.
crm-1 is acting upstream of the co-smad transducer encoded by
sma-4
To further characterize the role of crm-1 in the dbl-/sma
pathway, we used the body size phenotype in these mutant
animals as an indicator and manipulated the dbl-1 pathway
activity in the presence or absence of crm-1 to test for their
regulatory relationship. We showed that overexpression of sma-
4 cDNA using a hypodermis-specific promoter from dpy-13
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(from 0.72±0.06 mm to 1.21±0.09 mm). When this transgene
array was introduced into dbl-1 null mutant, wild-type body
length could not be restored (0.83±0.05 mm). Similarly, Wang
et al. (2005) have shown that an integrated sma-3 array cannot
rescue the defect in sma-6(wk7) mutant. Hence, a functional
ligand and its cognate receptors are required to initiate the
downstream signaling event acting through these Smad
molecules (Miyazono et al., 2005). Overexpression of the
downstream transducer molecules is in vain without the
initiating signal on the recipient cell surface. On the other
hand, elevation of the downstream sma-4 activity in wild-type
background will generate transgenic animals with slightly
increased body length (1.28±0.05 mm, pb0.01) (Table 1).
Interestingly, when these transgenic animals were fed with
bacteria expressing crm-1 dsRNA, no significant reduction of
body length was observed (1.27±0.07 mm) (Table 1). The
results imply that overexpression of sma-4 is epistatic to crm-1
depletion. The Sma phenotype of the crm-1(RNAi) animals
could be masked by constitutively supplying sma-4 function.
Consistent with this notion, a similar result was obtained in lon-
1 mutant animals. Mutations of lon-l, a downstream target of
the dbl/sma pathway, confers a long body phenotype (Morita et
al., 2002). The crm-1(RNAi) impact on the body length could be
nullified by the lon-1(e185) mutation and the crm-1(RNAi);
lon-1(e185) double mutant animals displayed a Lon phenotype
(Table 1).
Based on the above observation, crm-1 is acting upstream of
sma-4 and probably other R-Smad proteins encoded by sma-2
and sma-3 (Savage et al., 1996). If so, the crm-1 function would
be irrelevant in the absence of these Smad components. Indeed,
the mean body length of the crm-1(RNAi); sma-2(e502) double
mutants (0.73±0.04 mm) was almost the same as that of sma-2
mutants (0.72±0.03 mm) (Table 1).
crm-1 function requires both the dbl-1 ligand and the sma-6
receptor
If crm-1 acts upstream of the Smad, does it function via
interaction with the ligand or the receptors? The dbl-1 gene
functions in a dose-dependent manner to control nematode
body length (Morita et al., 1999; Suzuki et al., 1999). While
the dbl-1(nk3) mutant with complete absence of ligand
production displayed a mean body length of 0.82±0.03 mm,
heterozygous dbl-1(nk3) animals had a mean length of 1.09±
0.07 mm and transgenic animals over-expressing dbl-1 had a
mean length of 1.40±0.07 mm (Table 1). We showed that the
crm-1(RNAi) effect is sensitive to the dose of the dbl-1 ligand.
crm-1(RNAi) in dbl-1 (nk3) null mutants had no impact on the
body length (0.82±0.04 mm). The mean length of the crm-1
(RNAi) animals heterozygous of dbl-1(nk3) had a moderate
decrease of body length (1.00±0.06 mm, pb0.001), while the
same treatment reduced the body length more drastically from
1.40±0.07 mm to 1.17±0.10 mm in animals over-expressing
dbl-1. The results suggest that crm-1(RNAi) can exert its
impact on body length only when the DBL-1 ligands are
present. Moreover, dbl-1 overexpression could increase thebody length of crm-1(RNAi) animals to 1.17±0.10 mm from
1.03±0.08 mm in a wild-type background (pb0.001). There-
fore, crm-1 function is certainly dbl-1 activity-dependent.
This mutual suppression effect of dbl-1 overexpression and
crm-1(RNAi) also argues that crm-1 is acting in parallel to
the ligand action.
Interestingly, this same crm-1(RNAi) effect was not observed
in Bmp4 over-expressing animals (1.38±0.05 mm with crm-1
(RNAi) treatment versus 1.39±0.05 mm without treatment)
(Table 1). Evidently, CRM-1 is needed only to facilitate the
activity of the C. elegans DBL-1, but not the vertebrate BMP4.
Whether it suggests existence of a species-specific molecular
interaction, or additional auxiliary proteins are required for such
interaction with vertebrate ligand, remains to be investigated.
Nevertheless, increase of body length can be achieved by
overproducing the ligand molecule in the absence of the CRM-1
agonist. This feature argues that receptors are not the limiting
factor for controlling body length.
Similarly, we examined the crm-1 RNAi effect in two sma-6
alleles, wk7 and e1482. The sma-6(wk7) allele has a stop codon
in front of the kinase domain and is a molecular null displaying
a mean body length of 0.82±0.04 mm (Table 1) (Krishna et al.,
1999). crm-1(RNAi) on these sma-6(wk7) animals generated no
further shortening of body length (0.81±0.06 mm). In contrast,
while the sma-6(e1482) allele with residual receptor activity
displayed a weak Sma phenotype (0.89±0.03 mm) (Krishna et
al., 1999), crm-1(RNAi) treatment significantly reduced the
mean body length to 0.82±0.05 mm (pb0.001), close to that of
sma-6 null. These combined results suggest that the activity of
both dbl-1 and sma-6 is required for the wild type crm-1
function.
If crm-1 function is dependent on wild type copies of dbl-1
and sma-6, a possible route of regulation could be through
direct transcriptional activation of these two genes. Yet, when
dbl-1∷gfp and sma-6∷gfp transgenic animals were subjected
to crm-1(RNAi) treatment, no noticeable change of intensity nor
change of expressing cells was observed (data not shown),
suggesting that the agonistic interaction of crm-1, dbl-1 and
sma-6 is probably at the post-transcriptional level.
crm-1 and dbl-1 are co-expressed in the ventral nerve cord
To further distinguish whether crm-1 intercept dbl/sma
signaling via the ligand or the receptor, we examined the
expression pattern of different crm-1 transcripts using gfp
gene reporters in transgenic animals. Among the five predicted
crm-1 transcripts, all of them except crm-1b share a common
transcription initiation site as that for crm-1a. We constructed
two genomic gfp reporters harboring the locus sequence to
investigate their tissue expression patterns (Fig. 3A). In the
transgenic animals carrying pcrm-1a∷gfp reporter, consistent
signals were detected in neurons in the ventral nerve cord. By
the positions and clustering of the cell body as well as the
axonal outgrowth along the ventral nerve cord, crm-1a is
found to be expressed in the DA neurons 2 to 7, the DB
neurons 3 to 7 and additional neurons in the VA, VB and AS
classes along the nerve cord (VNC) (Fig. 3B). Expression was
Fig. 3. The expression pattern of the crm-1 gene. (A) Schematic representation of two crm-1 gene reporters. (B–D) crm-1a expression monitored by the pcrm-1a∷gfp
reporter is detected in neurons along the ventral nerve cord (arrows) (B), neurons in the pharyngeal region (C) and the RnA of the male tail sensory ray 2 (arrow) and 4
(arrowheads) (D). crm-1b expression was only detected in pharynx (E) and posterior gut (F). Scale bar=20 μm.
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male tail, gfp signals in the RnA neuronal cells of sensory rays
2 and 4 (Fig. 3D) and the PVR neuron with the entire axonal
process along the VNC were also observed (data not shown).
crm-1b expression was active in the entire pharynx (Fig. 3E)
and posterior gut (Fig. 3F). Since the body size defect of crm-
1(tm2218) mutant could be successfully rescued by the
genomic fragment used in pcrm-1a∷gfp reporter (mean
length=1.22±0.05 mm, pb0.001) which excludes the pro-
duction of crm-1b transcript, the expression pattern of crm-1a
should account for the biological function defined by the crm-
1 mutant.
dbl-1 is active in the VNC and has been detected in DA,
DB, VA and VB neurons of transgenic animals carrying a
rfp reporter driven by a 1.5 kb promoter sequence of dbl-1
(Morita et al., 1999; Suzuki et al., 1999) (Fig. 4C). In a
transgenic animal co-transformed with pcrm-1a∷gfp and
pdbl-1∷DsRed2(1.5k) reporters, overlapping expression of
crm-1 and dbl-1 was found in most of the neurons and their
processes (Fig. 4D), except a few scattered neurons, e.g.,
PVR neurons and some neurons of the AS class (data not
shown). Hence, crm-1 and dbl-1 may function in the same
cells.crm-1 functions non-autonomously in facilitating dbl-1 activity
If crm-1 and dbl-1 are co-expressed in the same cells, how
are they interacting with each other? Since neither crm-1 nor
dbl-1 was expressed in the GABAnergic neurons along the
VNC, these neurons would offer good ectopic expression sites
for a functional assessment. The unc-47 promoter active in 26
GABAnergic neurons (Eastman et al., 1999, Cinar et al.,
2005) showed neither overlapping expression with dbl-1
(Figs. 5B–D) nor crm-1 (Figs. 5F–H). When the dbl-1
cDNA was ectopically turned on with this unc-47 promoter in
dbl-1 null mutant, transgenic animals with DBL-1 product
made in these non-CRM-1-producing cells displayed a Lon
phenotype (1.39±0.07 mm, pb0.001) (Fig. 5I), a feature
resembling the dbl-1 overexpression lines (1.40±0.07 mm). In
addition, when the same unc-47 promoter was used to
ectopically express crm-1a cDNA in the crm-1 mutant, the
Sma body phenotype was significantly rescued (1.22±
0.09 mm, pb0.001). Since CRM-1 and DBL-1 can be
ectopically produced in cells where they are not normally
expressed and independently led to rescue of mutant
phenotype when their locales of synthesis are dissociated,
the CRM-1 facilitation of DBL-1 signaling probably occurs
Fig. 4. The overlapping expression of crm-1 and dbl-1 in the ventral nerve cord.
(A) DIC images of the animal. Expression patterns of crm-1 (B) and dbl-1 (C)
are revealed by the pcrm-1a∷gfp and pdbl-1∷rfp(1.5k) reporters, respectively.
Merged pattern of crm-1 and dbl-1 expression (D). The co-expressed DA
neurons and DB neurons are marked by arrows and arrowheads, respectively.
Scale bar=50 μm.
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potentially takes place.
Discussion
crm-1 is a critical but not the limiting factor for body length
determination
While there are plenty of reports on how the BMP signaling
events are modulated by secreted proteins with CR domains,
such a regulatory event has not been reported in C. elegans
(Little and Mullins, 2006). In this paper, we present the first
functional analysis of such a regulatory protein in C. elegans.
Several lines of evidence suggest a facilitating role of CRM-1
on BMP signaling. Using body length as an assessment
parameter, we showed that CRM-1 can enhance the BMP
signalling, although this activity was not noted in male tail
sensory organ patterning.
The small body phenotype of crm-1(tm2218) and crm-1
(RNAi) animals confirmed that crm-1 is important in developinga normal body size. The severity of their phenotypes suggests
that the crm-1 function, like that of the DBL-1 ligand and its
receptors, is also dose-dependent. crm-1, however, is not the
limiting factor that determines the body length in wild-type
animals. While increase of crm-1 activity could not result in an
increase of body length, elevated DBL-1 ligand production
alone can do so. That means, crm-1 activity is in excess in wild-
type animals and body length of the animals is primarily
influenced by the ligand concentration. Furthermore, crm-1
mutant animals displayed a reduction of hypodermal DNA
content due to a reduction of endoreplication in the hypodermal
nuclei, as the other dbl/sma mutants did. Hence, both the gross
body phenotype and the cellular defect consistently show that
crm-1 is acting in the dbl/sma pathway.
crm-1 is a new player in the nematode BMP signaling
Many C. elegans mutants with a small body size are
defective in component(s) of the BMP signaling pathway
(Savage-Dunn, 2001). sma-9 encodes a Schnürri zinc finger
transcription factor acting as a downstream component in
DBL-1 signaling pathway (Liang et al., 2003). The serine–
threonine kinase KIN-29 modulates TGF-β signaling to
regulate body size. Genetically, kin-29 is epistatic to dbl-1
and acts upstream of lon-1 (Maduzia et al., 2005). In addition,
the characterization of uncloned sma mutants and analysis of
their interactions with existing components in the Sma/Mab
pathway showed that sma-16, sma-17, sma-18 and sma-20
are epistatic to lon-1 and are probably acting further down-
stream in this pathway (Savage-Dunn et al., 2003). None of
these new sma mutants reveals any modulating function on
the extracellular ligand activity. Therefore, the crm-1 is the
first regulator gene in C. elegans acting on the ligand/receptor
level. The elucidation of its function may therefore shed light
on the role of its orthologs in developmental events in other
animal models.
Comparison of the body length of crm-1(RNAi) and dbl-1
mutant animals shows that severity of the phenotype of crm-1
(RNAi) animals is weaker than that of dbl-1 null mutants. If
dbl-1 function requires crm-1, their inequivalent phenotypes
must be explained. One possible reason would be the
ineffectiveness of knocking down the crm-1 gene primarily
expressed in the neuronal cells more resistant to RNAi
treatment (Kamath et al., 2001). In fact, RNAi treatments
targeting dbl-1 and sma-6 genes gave similar weak loss-of-
function phenotypes (data not shown). On the other hand, it is
possible that the dbl-1 function is not entirely dependent on
the crm-1 function. In the absence of crm-1 activity, residual
dbl-1 signal can propagate and be sufficient to prevent an
extreme reduction of body length as exhibited by null dbl-1
mutants. The independence of Xenopus Bmp4 from this crm-1
requirement certainly supports this second hypothesis. The
potent frog BMP4 does not require the CRM-1 activity at all
and is capable of generating long animals on its own. This
result also suggests that the nematode BMP receptors, SMA-6
and DAF-4, are not the limiting factors restricting the increase
of body length.
Fig. 5. Ectopic expression in GABAnergic neurons along the ventral nerve cord. The unc-47 promoter reporters show no overlapping pattern with crm-1 (B–D) nor
dbl-1 (F–H) reporters (arrows). The DIC images of the animals (A and E). Scale bar=20 μm. (I) Body length of wild type, crm-1 mutants, dbl-1 mutants and
transgenic animals with crm-1 or dbl-1 cDNA ectopically expressed by the unc-47 promoters in crm-1 or dbl-1 mutants, respectively. The body length of 100 five-
day-old hermaphrodites was measured. Error bars indicate standard errors. The asterisks indicate significant differences with p valueb0.001.
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We showed by genetic approach that crm-1 acts non-
autonomously outside the expressing cell to promote the dbl/sma pathway activity possibly through its interaction with the
DBL-1 ligand or/and its receptors. As a facilitator of DBL-1
signaling, CRM-1 may function in the ligand producing cells to
facilitate the ligand secretion process, or it may associate with
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possibility is that CRM-1 act as a co-receptor to augment the
ligand–receptor binding and thus strengthen the signalling
event. It is well documented that SMA-6 receptors are
synthesized in the pharynx, intestine, male tail and hypodermis
(Krishna et al., 1999), but only its expression in the hypodermis
is required for body size determination (Yoshida et al., 2001).
Consistent with this notion, the DAF-4 receptor is required only
in the hypodermis for determination of body length (Inoue and
Thomas, 2000). The hypodermis is the crucial tissue required
for body size regulation. When no crm-1 transcriptional activity
was detected in the hypodermis, crm-1 unlikely functions at this
receiving end of the signaling as a co-receptor.
Neurons along the ventral nerve cord serve as the source of
the DBL-1 signal, which globally regulates the body size
(Suzuki et al., 1999). Dual fluorescent reporter-labelling
showed that both crm-1 and dbl-1 are expressed in the same
cells along the VNC. If CRM-1 functions to facilitate DBL-1
ligand secretion in the same cell, ectopic expression of dbl-1
alone in GABAnergic neurons, which normally express neither
crm-1 nor dbl-1, should not rescue dbl-1 mutant phenotype.
However, such manipulation is sufficient to fully restore wild-
type morphology in dbl-1 mutant and generates an extension of
body length. Similarly, ectopic expression of crm-1 alone in
these GABAnergic neurons can also rescue crm-1 phenotype.
These results argue against that CRM-1 modulates the level of
ligand production in the expressing cells.
Under these circumstances, we are left with the option that
CRM-1 works extracellularly to control the DBL-1 activity
(Fig. 6). That means, CRM-1 may enhance cell–cell commu-
nication events that are dependent on the secreted DBL-1 ligand
and its cognate receptor function in the extracellular matrix.
Many CR domain-containing proteins are secreted molecules
that help to establish the BMP gradients in the extracellular
space through physical association. Their activity can be further
regulated by a class of metalloproteases, e.g., XOLLOID that
cleaves CHORDIN complexes at specific sites and generates
protein fragments with intact BMP-binding CR domains
(Larraín et al., 2000). A regulatory step of a similar nature
may be required for CRM-1 function. In fact, CRM-1 proteins
could interact with a variety of extracellular molecules in C.
elegans, some of which are matrix-associated metalloproteasesFig. 6. A model of crm-1 function in the BMP signaling pathway in C. elegans.
Both CRM-1 and DBL-1 are produced from the same neuronal cells. CRM-1
facilitates the presentation of DBL-1 in the extracellular space. The signaling
event acting via the SMA-6/DAF-4 receptors is transduced into the hypodermis
affecting its differentiation events.with regulatory activity (Li et al., 2004). Whether CRM-1
protein is cleaved and how it interacts with DBL-1 remain
unknown. As an alternative, the gene products of isoforms,
crm-1c and crm-1e, lacking any transmembrane domain could
account for this mode of CRM-1 action in the extracellular
matrix without invoking any processing step. Should these
cDNA isoforms be available, ectopic expression of them in
mutants will tell the functional roles of different isoforms apart.
On the other hand, we have not been able to demonstrate in our
preliminary study any direct physical interaction of CRM-1 and
DBL-1 in any in vivo or in vitro condition. The topology of the
CRM-1 molecule, however, has been ascertained using N-
terminal GFP fusion reporters. Both the signal peptide and
transmembrane domain properties have been confirmed,
suggesting CRM-1 to be localized on the membrane of the
expressing cells. So far, this finding is consistent with our
understanding about non-autonomous function of CRM-1.
Is the CRM-1 function conserved?
CRIM1 homologues have been identified in humans, mice,
chickens, zebrafish and worms (Kolle et al., 2000). Knock-
down of crim1 in zebrafish results in an expansion of the
ventral mesoderm-derived posterior blood island and loss of
pioneer muscle cells. The phenotypes are not consistent with a
role of crim1 in the dorso-ventral patterning, an event requiring
BMP signaling (Kinna et al., 2006). Disruption of crim1 gene
expression in mice results in cerebral edema, eye, rib, kidney
and skull defects (Pennisi et al., 2007). In the mouse embryo,
expression of Crim1 is detected in the notochord, somites,
floor plate, early motor neurons and interneuron of developing
spinal chord (Kolle et al., 2000). These patterns indeed overlap
spatially and temporally with that of Bmp4 and Bmp7,
although information of their products co-localization is
lacking. Our data from functional assay and expression
analysis at single cell level argue strongly that CRM-1
products do have an agonistic role in BMP signalling. The
demonstration of CRM-1 function in C. elegans as an
extracellular modulator would allow us to formulate hypoth-
esis and evaluate the impact of this modulator on ligand
diffusibility and presentation, which can be experimentally
tested. As a note of caution, because the effect of reducing
CRM-1 activity in the C. elegans could not be recapitulated
when the worm DBL-1 ligand was substituted by the Xenopus
BMP4, species-specific interaction should be considered when
molecular interaction is monitored.
In recent studies, a number of CR-containing proteins have
been found to contain additional domains. For example, the
Nel-like secreted protein (NELL) contains the EGF-like
domain for binding protein kinase C and a TSP-1-like domain
for heparin binding (Kuroda and Tanizawa, 1999; Kuroda et
al., 1999). Xenopus Kielin and Drosophila Crossveinless 2
(Cv-2) contain the vWF-D domain at the C-termini to promote
cell–cell interactions (Hunt and Barker, 1987). CRIM1 is the
first CR domain-containing protein with an IGFBP domain.
Many IGFBPs have been found to interact with IGF-I and/or
IGF-II in vitro (Kim et al., 1997). Members of this protein
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ing receptors and inhibit insulin signalling (Yamanaka et al.,
1997). Do CRM-1 and its vertebrate counterparts have the
same property that can potentially integrate multiple pathways
via its modular structure? Structural dissection of CRM-1
protein generated from different transcripts in worm should
allow us to address such issue systematically. Nonetheless,
RNAi knockdown specifically targeting the crm-1b transcript
generates no phenotype or any effect on the body length (data
not shown). This observation may simply be caused by the
ineffectiveness of RNAi treatment using fragment spanned
across the crm-1b specific region. Or, it is due to the lack of
an appropriate biological assay to reveal the activity of this
isoform. While this IGFBP domain may not be required for
the modulation of the dbl/sma pathway to control body
length, its specific expression in the pharyngeal bulb and gut
dictated by an alternative promoter does suggest its role in a
distinct developmental context. dbl signaling pathway has
been implicated to function in the induced immune response
via activation of lysozyme genes in the intestine (Mallo et al.,
2002). The same innate immunity depends on the daf-2/daf-
16 insulin-like growth factor pathway (Millet and Ewbank,
2004). Hence, we would not be surprised if this crm-1b
encoded product is specifically required in the digestive tract
to coordinate the activity of these two pathways. Certainly,
pathogen infection and animal resistance assays will be useful
to confirm this notion.
It is interesting to note that while early work often defined
the CR-containing molecules as BMP antagonists, an emerging
view is that a lot of these molecules have an agonistic effect on
BMP signaling. For example, the Cv-2 gene product promotes
the DPP signal at the CVs and the ends of LVs in Drosophila
wing, although Cv-2 product is structurally similar to a BMP
antagonizing factor, KIELIN (Conley et al., 2000; Matsui et al.,
2000). Similarly, the mammalian Crossveinless 2 and a related
molecule Kcp (aka Crim2) displayed a pro-BMP activity in
mouse organogenesis (Ikeya et al., 2006). The chordin-related
molecule encoded by Twisted gastrulation was found to
exhibit antagonistic and agonistic effect on BMP signaling
depending on its dosage manipulated by overexpression or
depletion (Xie and Fisher, 2005). Crm-1 can indeed be an
antagonist. Wilkinson et al. (2003) demonstrated that over-
expression of the human CRIM1 with BMP4 in metanephric
explant cultures resulted in a reduction of BMP secretion, thus
concluding that CRIM1 antagonizes BMP function by
blocking its cellular release. When crm-1 is found to be
coexpressed with dbl-1 in nematode, a conserved mechanism
in operation would have been expected. Nevertheless, crm-1
activity at the physiological level is clearly needed to enhance
the BMP activity specifically to hypodermal differentiation.
Moreover, crm-1 activity is dispensable for the male tail
sensory ray patterning, suggesting a differential impact of this
molecule in alternative biological processes. The difference in
tissue requirement may not necessarily suggest any contra-
dicting interpretation but simply highlights the variation of the
dbl-1 signaling events during the ontogenic development of
these animal models.Acknowledgments
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